Is “test to treat” too good to be true? Does it really matter who gets credit for CRISPR? And what’s the offramp for Covid-19?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Physician and researcher Kavita Patel joins us to explain why President Biden’s plans for Covid-19 — including an ambitious idea to distribute antiviral treatments — might not be so simple. We also discuss some milestone data in the quest to turn CRISPR into medicine and the latest twist in the quest to figure out who invented it.